There are 2789 resources available
425P - Cetuximab could be administered once every two weeks instead of once weekly
Presenter: sarah Lobet
Session: ePoster Display
426P - Spotlight on refractory metastatic colorectal cancer (refMCRC): Role of prognostic characteristics in the continuum of care
Presenter: Augusto Valdivia
Session: ePoster Display
281P - Prognostic impact of immune interactions in HER2+ and triple-negative breast cancer brain metastases
Presenter: Gaia Griguolo
Session: ePoster Display
282P - Methylthioadenosine phosphorylase (MTAP) genomic loss in ERBB2 amplified (amp) and mutated (mut) (ERBB2+) metastatic breast cancer (MBC)
Presenter: Abirami Sivapiragasam
Session: ePoster Display
283P - Treatment landscape of HER2-positive metastatic breast cancer (MBC): Results from the Austrian AGMT_MBC-Registry
Presenter: Simon Peter Gampenrieder
Session: ePoster Display
284P - Trastuzumab emtansine (T-DM1) in Asian patients with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC): Data from the phase III EMILIA study
Presenter: Seock-Ah Im
Session: ePoster Display
285P - Real-world outcomes associated with pyrotinib-based therapy for HER2-positive metastatic breast cancer
Presenter: Li Hao
Session: ePoster Display
286P - Outcome of patients with HER2-positive brain metastatic breast cancer: A 10-year retrospective study
Presenter: Cecile Bigot
Session: ePoster Display
287P - Burden of illness of HER2+ in metastatic breast cancer (MBC) patients: A systematic literature review (SLR)
Presenter: Gerard Vondeling
Session: ePoster Display